Genmab A/S (NASDAQ:GMAB) Receives Average Rating of “Moderate Buy” from Brokerages

Retrieved on: 2025-03-05 07:34:25

Tags for this article:

Genmab

Daratumumab

Short

Stock valuation

Marketbeat

Click the tags to see associated articles and topics

Genmab A/S (NASDAQ:GMAB) Receives Average Rating of “Moderate Buy” from Brokerages. View article details on hiswai:

Excerpt

Two Sigma Investments LP now owns 1,706,364 shares of the company's stock worth $35,612,000 after acquiring an additional 938,455 shares during the ...

Article found on: www.defenseworld.net

View Original Article